When viral oncoprotein meets tumor suppressor: A structural view

Genes and Development

Volumn 20, Issue 17, 2006, Pages 2332-2337

  Liu, Xin ^a   Marmorstein, Ronen ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ONCOPROTEIN; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN;

CANCER; DNA VIRUS; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; RNA VIRUS; SIMIAN VIRUS 40; VIRUS MORPHOLOGY; VIRUS TRANSMISSION; WART VIRUS;

HUMANS; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; TUMOR SUPPRESSOR PROTEINS;

EID: 33748250229     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1471706     Document Type: Review

References (67)

1. Adams, P.D., Li, X., Sellers, W.R., Baker, K.B., Leng, X., Harper, J.W., Taya, Y., and Kaelin Jr., W.G. 1999. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol. Cell. Biol. 19: 1068-1080.
2. Ahlquist, P. 2006. Parallels among positive-strand RNA viruses, reverse-transcribing viruses and double-stranded RNA viruses. Nat. Rev. Microbiol. 4: 371-382.
3. Ahlquist, P., Noueiry, A.O., Lee, W.M., Kushner, D.B., and Dye, B.T. 2003. Host factors in positive-strand RNA virus genome replication. J. Virol. 77: 8181-8186.
4. Ahuja, D., Saenz-Robles, M.T., and Pipas, J.M. 2005. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24: 7729-7745.
5. Baleja, J.D., Cherry, J.J., Liu, Z., Gao, H., Nicklaus, M.C., Voigt, J.H., Chen, J.J., and Androphy, E.J. 2006. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral Res. (in press).
6. Barlev, N.A., Liu, L., Chehab, N.H., Mansfield, K., Harris, K.G., Halazonetis, T.D., and Berger, S.L. 2001. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8: 1243-1254.
7. Bell, S., Klein, C., Muller, L., Hansen, S., and Buchner, J. 2002. p53 contains large unstructured regions in its native state. J. Mol. Biol. 322: 917-927.
8. Berk, A.J. 2005. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24: 7673-7685.
9. Brooks, C.L. and Gu, W. 2006. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21: 307-315.
10. Cho, Y., Gorina, S., Jeffrey, P.D., and Pavletich, N.P. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346-355.
11. Cobrinik, D. 2005. Pocket proteins and cell cycle control. Oncogene 24: 2796-2809.
12. Collot-Teixeira, S., Bass, J., Denis, F., and Ranger-Rogez, S. 2004. Human tumor suppressor p53 and DNA viruses. Rev. Med. Virol. 14: 301-319.
13. Coutts, A.S. and La Thangue, N. 2006. The p53 response during DNA damage: Impact of transcriptional cofactors. Biochem. Soc. Symp. 73: 181-189.
14. De Clercq, E. 2004. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2: 704-720.
15. Doorbar, J. 2005. The papillomavirus life cycle. J. Clin. Virol. 32 (Suppl. 1): S7-S15.
16. Dyson, H.J. and Wright, P.E. 2005. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6: 197-208.
17. Gai, D., Zhao, R., Li, D., Finkielstein, C.V., and Chen, X.S. 2004. Mechanisms of conformational change for a replicative hexameric helicase of SV40 large tumor antigen. Cell 119: 47-60.
18. Harbour, J.W. and Dean, D.C. 2000. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes & Dev. 14: 2393-2409.
19. Harbour, J.W., Luo, R.X., Dei Santi, A., Postigo, A.A., and Dean, D.C. 1999. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869.
20. Harris, S.L. and Levine, A.J. 2005. The p53 pathway: Positive and negative feedback loops. Oncogene 24: 2899-2908.
21. Hartwell, L.H. and Weinert, T.A. 1989. Checkpoints: Controls that ensure the order of cell cycle events. Science 246: 629-634.
22. Hensey, C.E., Hong, F., Durfee, T., Qian, Y.W., Lee, E.Y., and Lee, W.H. 1994. Identification of discrete structural domains in the retinoblastoma protein. Amino-terminal domain is required for its oligomerization. J. Biol. Chem. 269: 1380-1387.
23. Hickman, A.B. and Dyda, F. 2005. Binding and unwinding: SF3 viral helicases. Curr. Opin. Struct. Biol. 15: 77-85.
24. Ho, W.C., Fitzgerald, M.X., and Marmorstein, R. 2006. Structure of the p53 core domain dimer bound to DNA. J. Biol. Chem. 281: 20494-20502.
25. Hollingsworth Jr., R.E., Hensey, C.E., and Lee, W.H. 1993. Retinoblastoma protein and the cell cycle. Curr. Opin. Genet. Dev. 3: 55-62.
26. Horzinek MC. 1997. The birth of virology. Antonie van Leeuwenhoek 71: 15-20.
27. Hwang, S.G., Lee, D., Kim, J., Seo, T., and Choe, J. 2002. Human papillomavirus type 16 E7 binds to E2F1 and activates E2F1-driven transcription in a retinoblastoma protein-independent manner. J. Biol. Chem. 277: 2923-2930.
28. Jeffrey, P.D., Gorina, S., and Pavletich, N.P. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267: 1498-1502.
29. Kim, H.Y., Ahn, B.Y., and Cho, Y. 2001. Structural basis for the inactivation of retinoblastoma tumor suppressor by SV40 large T antigen. EMBO J. 20: 295-304.
30. Knudsen, E.S. and Wang, J.Y. 1997. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol. Cell. Biol. 17: 5771-5783.
31. Kussie, P.H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A.J., and Pavletich, N.P. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
32. Lane, D.P. 1992. Cancer. p53, guardian of the genome. Nature 358: 15-16.
33. Lee, C. and Cho, Y. 2002. Interactions of SV40 large T antigen and other viral proteins with retinoblastoma tumour suppressor. Rev. Med. Virol. 12: 81-92.
34. Lee, W., Harvey, T.S., Yin, Y., Yau, P., Litchfield, D., and Arrowsmith, C.H. 1994. Solution structure of the tetrameric minimum transforming domain of p53. Nat. Struct. Biol. 1: 877-890.
35. Lee, J.O., Russo, A.A., and Pavletich, N.P. 1998. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391: 859-865.
36. Lee, C., Chang, J.H., Lee, H.S., and Cho, Y. 2002. Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor. Genes & Dev. 16: 3199-3212.
37. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
38. _. 2001. The origins of virology. In Fields virology (eds. B.N. Fields, D.M. Knipe and P.M. Howley), pp. 1-14. Lippincott Williams & Wilkins, Philadelphia.
39. Li, X. and Coffino, P. 1996. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol. 70: 4509-4516.
40. Li, M., Chen, D., Shiloh, A., Luo, J., Nikolaev, A.Y., Qin, J., and Gu, W. 2002. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648-653.
41. Lilyestrom, W., Klein, M.G., Zhang, R., Joachimiak, A., and Chen, X.S. 2006. Crystal structure of SV40 large T-antigen bound to p53: Interplay between a viral oncoprotein and a cellular tumor suppressor. Genes & Dev. (this issue).
42. Liu, X., Clements, A., Zhao, K., and Marmorstein, R. 2006. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J. Biol. Chem. 281: 578-586.
43. Lowe, S.W., Cepero, E., and Evan, G. 2004. Intrinsic tumour suppression. Nature 432: 307-315.
44. Ma, B., Pan, Y., Gunasekaran, K., Venkataraghavan, R.B., Levine, A.J., and Nussinov, R. 2005. Comparison of the protein-protein interfaces in the p53-DNA crystal structures: Towards elucidation of the biological interface. Proc. Natl. Acad. Sci. 102: 3988-3993.
45. Munger, K., Baldwin, A., Edwards, K.M., Hayakawa, H., Nguyen, C.L., Owens, M., Grace, M., and Huh, K. 2004. Mechanisms of human papillomavirus- induced oncogenesis. J. Virol. 78: 11451-11460.
46. Neumann, G., Whitt, M.A., and Kawaoka, Y. 2002. A decade after the generation of a negative-sense RNA virus from cloned cDNA - What have we learned? J. Gen. Virol. 83: 2635-2662.
47. Nevins, J.R. 2001. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10: 699-703.
48. Nomine, Y., Masson, M., Charbonnier, S., Zanier, K., Ristriani, T., Deryckere, F., Sibler, A.P., Desplancq, D., Atkinson, R.A., Weiss, E., et al. 2006. Structural and functional analysis of E6 oncoprotein: Insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol. Cell 21: 665-678.
49. O'Shea, C.C. 2005. DNA tumor viruses - The spies who lyse us. Curr. Opin. Genet. Dev. 15: 18-26.
50. Ohlenschlager, O., Seiboth, T., Zengerling, H., Briese, L., Marchanka, A., Ramachandran, R., Baum, M., Korbas, M., Meyer-Klaucke, W., Durst, M., et al. 2006. Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7. Oncogene (in press).
51. Patrick, D.R., Oliff, A., and Heimbrook, D.C. 1994. Identification of a novel retinoblastoma gene product binding site on human papillomavirus type 16 E7 protein. J. Biol. Chem. 269: 6842-6850.
52. Pietenpol, J.A., Tokino, T., Thiagalingam, S., el-Deiry, W.S., Kinzler, K.W., and Vogelstein, B. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. 91: 1998-2002.
53. Ramig, R.F. 1997. Genetics of the rotaviruses. Annu. Rev. Microbiol. 51: 225-255.
54. Rubin, S.M., Gall, A.L., Zheng, N., and Pavletich, N.P. 2005. Structure of the Rb C-terminal domain bound to E2F1-DP1: A mechanism for phosphorylation-induced E2F release. Cell 123: 1093-1106.
55. Scheffner, M., Huibregtse, J.M., Vierstra, R.D., and Howley, P.M. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
56. Sherr, C.J. 2004. Principles of tumor suppression. Cell 116: 235-246.
57. Sherr, C.J. and McCormick, F. 2002. The RB and p53 pathways in cancer. Cancer Cell 2: 103-112.
58. Singh, M., Krajewski, M., Mikolajka, A., and Holak, T.A. 2005. Molecular determinants for the complex formation between the retinoblastoma protein and LXCXE sequences. J. Biol. Chem. 280: 37868-37876.
59. Smith, J. 2002. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol. 12: 404-406.
60. Steegenga, W.T., van der Eb, A.J., and Jochemsen, A.G. 1996. How phosphorylation regulates the activity of p53. J. Mol. Biol. 263: 103-113.
61. Stevaux, O. and Dyson, N.J. 2002. A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 14: 684-691.
62. Temin, H.M. and Baltimore, D. 1972. RNA-directed DNA synthesis and RNA tumor viruses. Adv. Virus Res. 17: 129-186.
63. Waterman, M.J., Stavridi, E.S., Waterman, J.L., and Halazonetis, T.D. 1998. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 19: 175-178.
64. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
65. _. 1997. The cat and mouse games that genes, viruses, and cells play. Cell 88: 573-575.
66. Xiao, B., Spencer, J., Clements, A., Ali-Khan, N., Mittnacht, S., Broceno, C., Burghammer, M., Perrakis, A., Marmorstein, R., and Gamblin, S.J. 2003. Crystal structure of the retinoblastoma tumor suppressor protein bound to E2F and the molecular basis of its regulation. Proc. Natl. Acad. Sci. 100: 2363-2368.
67. Zhao, K., Chai, X., Johnston, K., Clements, A., and Marmorstein, R. 2001. Crystal structure of the mouse p53 core DNA-binding domain at 2.7 A resolution. J. Biol. Chem. 276: 12120-12127.